25/10/2010
Afghanistan
New bivalent polio vaccine playing key role in global polio eradication
Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial
A head to head trial against current poliovirus vaccines has found that the new bivalent oral vaccine against poliovirus, which targets both the remaining types of poliovirus concurrently, induces a stronger immune response than the traditional trivalent vaccine and a similar immune response to the latest monovalent (monovalent type 1 or monovalent type 3) vaccines. Furthermore, it is easier to administer, allowing children to be immunised against the two remaining types of wild poliovirus in a single oral dose. These are the conclusions of an Article published Online First in The Lancet.
For details, please go to:
http://www.thelancet.com
Related News
21/03/2023
21 March 2023
Notice: Undefined variable: default_image in /var/www/vhosts/polioeradication.org/httpdocs/wp-content/themes/gpei/single-news.php on line 121
16/03/2023
16 March 2023
15/03/2023
Rotary International President, Jennifer Jones, is on a brief tour of London. Speaking at the House of Commons she said that Rotary had to deliver on its promise to the children of the world that it would help to eradicate polio.
10/03/2023
On Tuesday 28 February 2023, ministers and high-level delegates from across the Eastern Mediterranean Region participated in the seventh meeting of the Regional Subcommittee for Polio Eradication and Outbreaks.
09/03/2023
Latest recommendations from independent global certification body
08/03/2023
In the polio eradication programme, women are forces to be reckoned with. They play important and integral roles at all levels of the programme. We got the perspectives of four women from WHO EMRO who tap into digital innovations to shape decision-making
